Abstract
Objectives: The Objectives of this study is to demonstrate the response of patients with neurocognitive disorders to a combination of antidementia drugs and repetitive transcranial magnetic stimulation (rTMS).Methods: We conducted a descriptive and retrospective study with a sample of 13 geriatric patients, randomly selected from the private psychogeriatric clinic at the Nina Institute of Clinical Neurosciences in Santo Domingo. These patients were presented with various neurocognitive disorders: 3 with mild cognitive impairment, 3 with Alzheimer’s dementia, 2 with vascular dementia, and 5 with mixed dementia. All patients signed an informed consent form. Prior to starting rTMS treatment, they underwent EEG, laboratory analysis, and neuropsychological testing using the Mini-Mental State Examination (MMSE). Additionally, they were medicated with rivastigmine (12 mg) and memantine (20 mg). The rTMS parameters for the 20-session protocol were as follows: for mild cognitive impairment, 110% motor threshold (MT), 10 Hz, and 2,000 pulses; for Alzheimer’s diagnosis, 80% MT, 20 Hz, 1,200 pulses, 80% MT, 5 Hz, 600 pulses, and theta wave at 10 Hz, 110% MT, and 2,500 pulses. The results were tabulated, and consistent were drawn.Results: Our findings showed that all the patients improved their levels of cognitive impairment.Conclusions: Patients improved their cognitive impairment level with the combination treatment of antidementia drugs: cholinesterase inhibitors and memantine, along with repetitive transcranial magnetic stimulation (rTMS). Repetitive transcranial magnetic stimulation (rTMS) is a developing treatment, and further clinical studies are needed to confirm its potential in treating Alzheimer’s disease and other neurocognitive disorders alongside antidementia medications.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call